(LXS) LANXESS Aktiengesellschaft - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0005470405
Stock: Disinfectants, Flame Retardants, Plasticizers, Pigments, Intermediates
Total Rating 29
Risk 74
Buy Signal -0.58
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.39% |
| Yield on Cost 5y | 0.17% |
| Yield CAGR 5y | -43.77% |
| Payout Consistency | 89.2% |
| Payout Ratio | 13.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 41.6% |
| Relative Tail Risk | -10.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.66 |
| Alpha | -38.85 |
| Character TTM | |
|---|---|
| Beta | 0.437 |
| Beta Downside | 0.722 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.32% |
| CAGR/Max DD | -0.37 |
Description: LXS LANXESS Aktiengesellschaft January 13, 2026
LANXESS Aktiengesellschaft (XETRA:LXS) is a German specialty-chemicals group that develops, manufactures and markets a broad portfolio of chemical intermediates, additives and consumer-protection products. Its operations are organized into three segments – Consumer Protection, Specialty Additives and Advanced Intermediates – serving end-markets such as agro-chemicals, automotive, construction, flavors & fragrances, semiconductors and photovoltaic technologies.
Key quantitative signals (2023-24 public filings) show revenue of roughly €5.9 billion, an adjusted EBITDA margin of about 12 % and a 2023 R&D spend of €340 million, reflecting a focus on high-value, application-specific chemistry. The business is sensitive to petro-chemical feed-stock prices and to EU regulatory trends (e.g., REACH and the European Green Deal), while demand for lightweight polymers, battery-grade additives and water-purification solutions are identified as primary growth drivers for the sector.
For a deeper, data-driven valuation of LXS, you may find the analyst tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -243.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.86 > 1.0 |
| NWC/Revenue: 28.21% < 20% (prev 25.86%; Δ 2.35% < -1%) |
| CFO/TA 0.05 > 3% & CFO 432.0m > Net Income -243.0m |
| Net Debt (-329.0m) to EBITDA (450.0m): -0.73 < 3 |
| Current Ratio: 2.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 20.52% > 18% (prev 0.19%; Δ 2032 % > 0.5%) |
| Asset Turnover: 66.79% > 50% (prev 66.88%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: -4.31 > 6 (EBITDA TTM 450.0m / Interest Expense TTM 42.0m) |
Altman Z'' 1.10
| A: 0.20 (Total Current Assets 2.70b - Total Current Liabilities 1.03b) / Total Assets 8.18b |
| B: -0.02 (Retained Earnings -179.0m / Total Assets 8.18b) |
| C: -0.02 (EBIT TTM -181.0m / Avg Total Assets 8.82b) |
| D: -0.02 (Book Value of Equity -93.0m / Total Liabilities 4.28b) |
| Altman-Z'' Score: 1.10 = BB |
Beneish M -3.35
| DSRI: 0.81 (Receivables 527.0m/700.0m, Revenue 5.89b/6.32b) |
| GMI: 0.94 (GM 20.52% / 19.39%) |
| AQI: 1.03 (AQ_t 0.41 / AQ_t-1 0.40) |
| SGI: 0.93 (Revenue 5.89b / 6.32b) |
| TATA: -0.08 (NI -243.0m - CFO 432.0m) / TA 8.18b) |
| Beneish M-Score: -3.35 (Cap -4..+1) = AA |
What is the price of LXS shares?
As of February 08, 2026, the stock is trading at EUR 19.32 with a total of 388,119 shares traded.
Over the past week, the price has changed by +10.65%, over one month by +9.77%, over three months by +13.38% and over the past year by -30.41%.
Over the past week, the price has changed by +10.65%, over one month by +9.77%, over three months by +13.38% and over the past year by -30.41%.
Is LXS a buy, sell or hold?
LANXESS Aktiengesellschaft has no consensus analysts rating.
What are the forecasts/targets for the LXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18.6 | -3.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16.5 | -14.8% |
LXS Fundamental Data Overview February 03, 2026
Market Cap USD = 1.78b (1.51b EUR * 1.1801 EUR.USD)
P/E Forward = 14.5773
P/S = 0.256
P/B = 0.3876
P/EG = 1.1165
Revenue TTM = 5.89b EUR
EBIT TTM = -181.0m EUR
EBITDA TTM = 450.0m EUR
Long Term Debt = 2.40b EUR (from longTermDebt, last quarter)
Short Term Debt = 74.0m EUR (from shortTermDebt, last quarter)
Debt = 2.48b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -329.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.60b EUR (1.51b + Debt 2.48b - CCE 391.0m)
Interest Coverage Ratio = -4.31 (Ebit TTM -181.0m / Interest Expense TTM 42.0m)
EV/FCF = 32.10x (Enterprise Value 3.60b / FCF TTM 112.0m)
FCF Yield = 3.11% (FCF TTM 112.0m / Enterprise Value 3.60b)
FCF Margin = 1.90% (FCF TTM 112.0m / Revenue TTM 5.89b)
Net Margin = -4.13% (Net Income TTM -243.0m / Revenue TTM 5.89b)
Gross Margin = 20.52% ((Revenue TTM 5.89b - Cost of Revenue TTM 4.68b) / Revenue TTM)
Gross Margin QoQ = 18.98% (prev 22.31%)
Tobins Q-Ratio = 0.44 (Enterprise Value 3.60b / Total Assets 8.18b)
Interest Expense / Debt = 0.36% (Interest Expense 9.00m / Debt 2.48b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -135.8m (EBIT -181.0m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.60 (Total Current Assets 2.70b / Total Current Liabilities 1.03b)
Debt / Equity = 0.64 (Debt 2.48b / totalStockholderEquity, last quarter 3.90b)
Debt / EBITDA = -0.73 (Net Debt -329.0m / EBITDA 450.0m)
Debt / FCF = -2.94 (Net Debt -329.0m / FCF TTM 112.0m)
Total Stockholder Equity = 4.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.76% (Net Income -243.0m / Total Assets 8.18b)
RoE = -5.77% (Net Income TTM -243.0m / Total Stockholder Equity 4.21b)
RoCE = -2.74% (EBIT -181.0m / Capital Employed (Equity 4.21b + L.T.Debt 2.40b))
RoIC = -2.76% (negative operating profit) (NOPAT -135.8m / Invested Capital 4.91b)
WACC = 3.01% (E(1.51b)/V(3.99b) * Re(7.52%) + D(2.48b)/V(3.99b) * Rd(0.36%) * (1-Tc(0.25)))
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈86.4m ; Y1≈56.7m ; Y5≈25.9m
Fair Price DCF = 13.36 (EV 824.5m - Net Debt -329.0m = Equity 1.15b / Shares 86.3m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -51.03 | EPS CAGR: -32.31% | SUE: 0.84 | # QB: 0
Revenue Correlation: -89.73 | Revenue CAGR: -11.12% | SUE: -1.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.36 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.14 | Chg30d=-0.036 | Revisions Net=-3 | Growth EPS=+269.0% | Growth Revenue=-0.5%
P/E Forward = 14.5773
P/S = 0.256
P/B = 0.3876
P/EG = 1.1165
Revenue TTM = 5.89b EUR
EBIT TTM = -181.0m EUR
EBITDA TTM = 450.0m EUR
Long Term Debt = 2.40b EUR (from longTermDebt, last quarter)
Short Term Debt = 74.0m EUR (from shortTermDebt, last quarter)
Debt = 2.48b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -329.0m EUR (from netDebt column, last quarter)
Enterprise Value = 3.60b EUR (1.51b + Debt 2.48b - CCE 391.0m)
Interest Coverage Ratio = -4.31 (Ebit TTM -181.0m / Interest Expense TTM 42.0m)
EV/FCF = 32.10x (Enterprise Value 3.60b / FCF TTM 112.0m)
FCF Yield = 3.11% (FCF TTM 112.0m / Enterprise Value 3.60b)
FCF Margin = 1.90% (FCF TTM 112.0m / Revenue TTM 5.89b)
Net Margin = -4.13% (Net Income TTM -243.0m / Revenue TTM 5.89b)
Gross Margin = 20.52% ((Revenue TTM 5.89b - Cost of Revenue TTM 4.68b) / Revenue TTM)
Gross Margin QoQ = 18.98% (prev 22.31%)
Tobins Q-Ratio = 0.44 (Enterprise Value 3.60b / Total Assets 8.18b)
Interest Expense / Debt = 0.36% (Interest Expense 9.00m / Debt 2.48b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -135.8m (EBIT -181.0m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.60 (Total Current Assets 2.70b / Total Current Liabilities 1.03b)
Debt / Equity = 0.64 (Debt 2.48b / totalStockholderEquity, last quarter 3.90b)
Debt / EBITDA = -0.73 (Net Debt -329.0m / EBITDA 450.0m)
Debt / FCF = -2.94 (Net Debt -329.0m / FCF TTM 112.0m)
Total Stockholder Equity = 4.21b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.76% (Net Income -243.0m / Total Assets 8.18b)
RoE = -5.77% (Net Income TTM -243.0m / Total Stockholder Equity 4.21b)
RoCE = -2.74% (EBIT -181.0m / Capital Employed (Equity 4.21b + L.T.Debt 2.40b))
RoIC = -2.76% (negative operating profit) (NOPAT -135.8m / Invested Capital 4.91b)
WACC = 3.01% (E(1.51b)/V(3.99b) * Re(7.52%) + D(2.48b)/V(3.99b) * Rd(0.36%) * (1-Tc(0.25)))
Discount Rate = 7.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈86.4m ; Y1≈56.7m ; Y5≈25.9m
Fair Price DCF = 13.36 (EV 824.5m - Net Debt -329.0m = Equity 1.15b / Shares 86.3m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -51.03 | EPS CAGR: -32.31% | SUE: 0.84 | # QB: 0
Revenue Correlation: -89.73 | Revenue CAGR: -11.12% | SUE: -1.05 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.36 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.14 | Chg30d=-0.036 | Revisions Net=-3 | Growth EPS=+269.0% | Growth Revenue=-0.5%